A Chemoproteomic Approach to Query the Degradable Kinome Using a Multi-kinase Degrader.Cell Chem Biol. 2018 Jan 18;25(1):88-99.e6. PMID:29129717 DOI:10.1016/j.chembiol.2017.10.005
~ 100 %
Homolog-Selective Degradation as a Strategy to Probe the Function of CDK6 in AML.Cell Chem Biol. 2019 Feb 21;26(2):300-306.e9. PMID:30595531 DOI:10.1016/j.chembiol.2018.11.006
~ 100 %
Homolog-Selective Degradation as a Strategy to Probe the Function of CDK6 in AML.Cell Chem Biol. 2019 Feb 21;26(2):300-306.e9. PMID:30595531 DOI:10.1016/j.chembiol.2018.11.006
Development of Dual and Selective Degraders of Cyclin-Dependent Kinases 4 and 6.Angew Chem Int Ed Engl. 2019 May 6;58(19):6321-6326. PMID:30802347 DOI:10.1002/anie.201901336
Development of Dual and Selective Degraders of Cyclin-Dependent Kinases 4 and 6.Angew Chem Int Ed Engl. 2019 May 6;58(19):6321-6326. PMID:30802347 DOI:10.1002/anie.201901336
Development of Dual and Selective Degraders of Cyclin-Dependent Kinases 4 and 6.Angew Chem Int Ed Engl. 2019 May 6;58(19):6321-6326. PMID:30802347 DOI:10.1002/anie.201901336
Development of Dual and Selective Degraders of Cyclin-Dependent Kinases 4 and 6.Angew Chem Int Ed Engl. 2019 May 6;58(19):6321-6326. PMID:30802347 DOI:10.1002/anie.201901336
Development of Dual and Selective Degraders of Cyclin-Dependent Kinases 4 and 6.Angew Chem Int Ed Engl. 2019 May 6;58(19):6321-6326. PMID:30802347 DOI:10.1002/anie.201901336
Development of Dual and Selective Degraders of Cyclin-Dependent Kinases 4 and 6.Angew Chem Int Ed Engl. 2019 May 6;58(19):6321-6326. PMID:30802347 DOI:10.1002/anie.201901336
Development of Dual and Selective Degraders of Cyclin-Dependent Kinases 4 and 6.Angew Chem Int Ed Engl. 2019 May 6;58(19):6321-6326. PMID:30802347 DOI:10.1002/anie.201901336
Development of Dual and Selective Degraders of Cyclin-Dependent Kinases 4 and 6.Angew Chem Int Ed Engl. 2019 May 6;58(19):6321-6326. PMID:30802347 DOI:10.1002/anie.201901336
Development of Dual and Selective Degraders of Cyclin-Dependent Kinases 4 and 6.Angew Chem Int Ed Engl. 2019 May 6;58(19):6321-6326. PMID:30802347 DOI:10.1002/anie.201901336
Development of Dual and Selective Degraders of Cyclin-Dependent Kinases 4 and 6.Angew Chem Int Ed Engl. 2019 May 6;58(19):6321-6326. PMID:30802347 DOI:10.1002/anie.201901336
Development of Dual and Selective Degraders of Cyclin-Dependent Kinases 4 and 6.Angew Chem Int Ed Engl. 2019 May 6;58(19):6321-6326. PMID:30802347 DOI:10.1002/anie.201901336
Development of Dual and Selective Degraders of Cyclin-Dependent Kinases 4 and 6.Angew Chem Int Ed Engl. 2019 May 6;58(19):6321-6326. PMID:30802347 DOI:10.1002/anie.201901336
Development of Dual and Selective Degraders of Cyclin-Dependent Kinases 4 and 6.Angew Chem Int Ed Engl. 2019 May 6;58(19):6321-6326. PMID:30802347 DOI:10.1002/anie.201901336
Development of Dual and Selective Degraders of Cyclin-Dependent Kinases 4 and 6.Angew Chem Int Ed Engl. 2019 May 6;58(19):6321-6326. PMID:30802347 DOI:10.1002/anie.201901336
Development of Dual and Selective Degraders of Cyclin-Dependent Kinases 4 and 6.Angew Chem Int Ed Engl. 2019 May 6;58(19):6321-6326. PMID:30802347 DOI:10.1002/anie.201901336
Development of Dual and Selective Degraders of Cyclin-Dependent Kinases 4 and 6.Angew Chem Int Ed Engl. 2019 May 6;58(19):6321-6326. PMID:30802347 DOI:10.1002/anie.201901336
Selective degradation of CDK6 by a palbociclib based PROTAC.Bioorg Med Chem Lett. 2019 Jun 1;29(11):1375-1379. PMID:30935795 DOI:10.1016/j.bmcl.2019.03.035
Selective degradation of CDK6 by a palbociclib based PROTAC.Bioorg Med Chem Lett. 2019 Jun 1;29(11):1375-1379. PMID:30935795 DOI:10.1016/j.bmcl.2019.03.035
Selective degradation of CDK6 by a palbociclib based PROTAC.Bioorg Med Chem Lett. 2019 Jun 1;29(11):1375-1379. PMID:30935795 DOI:10.1016/j.bmcl.2019.03.035
Selective degradation of CDK6 by a palbociclib based PROTAC.Bioorg Med Chem Lett. 2019 Jun 1;29(11):1375-1379. PMID:30935795 DOI:10.1016/j.bmcl.2019.03.035
Selective degradation of CDK6 by a palbociclib based PROTAC.Bioorg Med Chem Lett. 2019 Jun 1;29(11):1375-1379. PMID:30935795 DOI:10.1016/j.bmcl.2019.03.035
= 2.1 nM
= 89 %
Potent and Preferential Degradation of CDK6 via Proteolysis Targeting Chimera Degraders.J Med Chem. 2019 Aug 22;62(16):7575-7582. PMID:31330105 DOI:10.1021/acs.jmedchem.9b00871
= 1.1 nM
Potent and Preferential Degradation of CDK6 via Proteolysis Targeting Chimera Degraders.J Med Chem. 2019 Aug 22;62(16):7575-7582. PMID:31330105 DOI:10.1021/acs.jmedchem.9b00871
= 1.6 nM
Potent and Preferential Degradation of CDK6 via Proteolysis Targeting Chimera Degraders.J Med Chem. 2019 Aug 22;62(16):7575-7582. PMID:31330105 DOI:10.1021/acs.jmedchem.9b00871
= 1.7 nM
Potent and Preferential Degradation of CDK6 via Proteolysis Targeting Chimera Degraders.J Med Chem. 2019 Aug 22;62(16):7575-7582. PMID:31330105 DOI:10.1021/acs.jmedchem.9b00871
= 5.3 nM
Potent and Preferential Degradation of CDK6 via Proteolysis Targeting Chimera Degraders.J Med Chem. 2019 Aug 22;62(16):7575-7582. PMID:31330105 DOI:10.1021/acs.jmedchem.9b00871
= 8.6 nM
Potent and Preferential Degradation of CDK6 via Proteolysis Targeting Chimera Degraders.J Med Chem. 2019 Aug 22;62(16):7575-7582. PMID:31330105 DOI:10.1021/acs.jmedchem.9b00871
= 10.6 nM
Potent and Preferential Degradation of CDK6 via Proteolysis Targeting Chimera Degraders.J Med Chem. 2019 Aug 22;62(16):7575-7582. PMID:31330105 DOI:10.1021/acs.jmedchem.9b00871
= 24.2 nM
Potent and Preferential Degradation of CDK6 via Proteolysis Targeting Chimera Degraders.J Med Chem. 2019 Aug 22;62(16):7575-7582. PMID:31330105 DOI:10.1021/acs.jmedchem.9b00871
= 31 nM
Potent and Preferential Degradation of CDK6 via Proteolysis Targeting Chimera Degraders.J Med Chem. 2019 Aug 22;62(16):7575-7582. PMID:31330105 DOI:10.1021/acs.jmedchem.9b00871
= 81.6 nM
Potent and Preferential Degradation of CDK6 via Proteolysis Targeting Chimera Degraders.J Med Chem. 2019 Aug 22;62(16):7575-7582. PMID:31330105 DOI:10.1021/acs.jmedchem.9b00871
= 86.8 nM
Potent and Preferential Degradation of CDK6 via Proteolysis Targeting Chimera Degraders.J Med Chem. 2019 Aug 22;62(16):7575-7582. PMID:31330105 DOI:10.1021/acs.jmedchem.9b00871
= 129.7 nM
Potent and Preferential Degradation of CDK6 via Proteolysis Targeting Chimera Degraders.J Med Chem. 2019 Aug 22;62(16):7575-7582. PMID:31330105 DOI:10.1021/acs.jmedchem.9b00871
= 145.5 nM
Potent and Preferential Degradation of CDK6 via Proteolysis Targeting Chimera Degraders.J Med Chem. 2019 Aug 22;62(16):7575-7582. PMID:31330105 DOI:10.1021/acs.jmedchem.9b00871
= 271.9 nM
Potent and Preferential Degradation of CDK6 via Proteolysis Targeting Chimera Degraders.J Med Chem. 2019 Aug 22;62(16):7575-7582. PMID:31330105 DOI:10.1021/acs.jmedchem.9b00871
Potent and Preferential Degradation of CDK6 via Proteolysis Targeting Chimera Degraders.J Med Chem. 2019 Aug 22;62(16):7575-7582. PMID:31330105 DOI:10.1021/acs.jmedchem.9b00871
Potent and Preferential Degradation of CDK6 via Proteolysis Targeting Chimera Degraders.J Med Chem. 2019 Aug 22;62(16):7575-7582. PMID:31330105 DOI:10.1021/acs.jmedchem.9b00871
Potent and Preferential Degradation of CDK6 via Proteolysis Targeting Chimera Degraders.J Med Chem. 2019 Aug 22;62(16):7575-7582. PMID:31330105 DOI:10.1021/acs.jmedchem.9b00871
Potent and Preferential Degradation of CDK6 via Proteolysis Targeting Chimera Degraders.J Med Chem. 2019 Aug 22;62(16):7575-7582. PMID:31330105 DOI:10.1021/acs.jmedchem.9b00871
Potent and Preferential Degradation of CDK6 via Proteolysis Targeting Chimera Degraders.J Med Chem. 2019 Aug 22;62(16):7575-7582. PMID:31330105 DOI:10.1021/acs.jmedchem.9b00871
Potent and Preferential Degradation of CDK6 via Proteolysis Targeting Chimera Degraders.J Med Chem. 2019 Aug 22;62(16):7575-7582. PMID:31330105 DOI:10.1021/acs.jmedchem.9b00871
Potent and Preferential Degradation of CDK6 via Proteolysis Targeting Chimera Degraders.J Med Chem. 2019 Aug 22;62(16):7575-7582. PMID:31330105 DOI:10.1021/acs.jmedchem.9b00871
Potent and Preferential Degradation of CDK6 via Proteolysis Targeting Chimera Degraders.J Med Chem. 2019 Aug 22;62(16):7575-7582. PMID:31330105 DOI:10.1021/acs.jmedchem.9b00871
Potent and Preferential Degradation of CDK6 via Proteolysis Targeting Chimera Degraders.J Med Chem. 2019 Aug 22;62(16):7575-7582. PMID:31330105 DOI:10.1021/acs.jmedchem.9b00871
Potent and Preferential Degradation of CDK6 via Proteolysis Targeting Chimera Degraders.J Med Chem. 2019 Aug 22;62(16):7575-7582. PMID:31330105 DOI:10.1021/acs.jmedchem.9b00871
Potent and Preferential Degradation of CDK6 via Proteolysis Targeting Chimera Degraders.J Med Chem. 2019 Aug 22;62(16):7575-7582. PMID:31330105 DOI:10.1021/acs.jmedchem.9b00871
Potent and Preferential Degradation of CDK6 via Proteolysis Targeting Chimera Degraders.J Med Chem. 2019 Aug 22;62(16):7575-7582. PMID:31330105 DOI:10.1021/acs.jmedchem.9b00871
Potent and Preferential Degradation of CDK6 via Proteolysis Targeting Chimera Degraders.J Med Chem. 2019 Aug 22;62(16):7575-7582. PMID:31330105 DOI:10.1021/acs.jmedchem.9b00871
Selective CDK6 degradation mediated by cereblon, VHL, and novel IAP-recruiting PROTACs.Bioorg Med Chem Lett. 2020 May 1;30(9):127106. PMID:32184044 DOI:10.1016/j.bmcl.2020.127106
Selective CDK6 degradation mediated by cereblon, VHL, and novel IAP-recruiting PROTACs.Bioorg Med Chem Lett. 2020 May 1;30(9):127106. PMID:32184044 DOI:10.1016/j.bmcl.2020.127106
Selective CDK6 degradation mediated by cereblon, VHL, and novel IAP-recruiting PROTACs.Bioorg Med Chem Lett. 2020 May 1;30(9):127106. PMID:32184044 DOI:10.1016/j.bmcl.2020.127106
Selective CDK6 degradation mediated by cereblon, VHL, and novel IAP-recruiting PROTACs.Bioorg Med Chem Lett. 2020 May 1;30(9):127106. PMID:32184044 DOI:10.1016/j.bmcl.2020.127106
Selective CDK6 degradation mediated by cereblon, VHL, and novel IAP-recruiting PROTACs.Bioorg Med Chem Lett. 2020 May 1;30(9):127106. PMID:32184044 DOI:10.1016/j.bmcl.2020.127106
Selective CDK6 degradation mediated by cereblon, VHL, and novel IAP-recruiting PROTACs.Bioorg Med Chem Lett. 2020 May 1;30(9):127106. PMID:32184044 DOI:10.1016/j.bmcl.2020.127106
Selective CDK6 degradation mediated by cereblon, VHL, and novel IAP-recruiting PROTACs.Bioorg Med Chem Lett. 2020 May 1;30(9):127106. PMID:32184044 DOI:10.1016/j.bmcl.2020.127106